Multicenter retrospective study of the Efficacy of Adjuvant Immunotherapy after Radical therapy (Surgery or Radiotherapy) for Urothelial Carcinoma (Michinoku Study 1015)

Multicenter retrospective study of the Efficacy of Adjuvant Immunotherapy after Radical therapy (Surgery or Radiotherapy) for Urothelial Carcinoma (Michinoku Study 1015) - Multicenter retrospective study of the Efficacy of Adjuvant Immunotherapy after Radical therapy for Urothelial Carcinoma (Michinoku Study 1015)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054315

Enrollment

2500

Registered

2024-05-07

Start date

2024-05-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients between 18 and 100 years of age, with a pathologic diagnosis of urothelial carcinoma of the urethra, who have undergone total cystectomy, total nephroureterectomy, or local radiation therapy. Urothelial carcinoma is included in urothelial carcinoma. Period of case collection: January 2005 - March 31, 2031.

Exclusion criteria

Exclusion criteria: Patients with urothelial carcinoma (bladder cancer, cancer of the renal pelvis and ureter) for which treatment intervention is unknown, patients for whom important outcomes (recurrence, death, date of last confirmed survival, etc.) are unknown, patients who cannot be followed for observation periods of less than 3 months, etc., and patients who have indicated refusal to participate.

Design outcomes

Primary

Measure	Time frame
The efficacy (progression-free survival, cancer-specific survival, and overall survival) of immunotherapy after local treatment for urothelial carcinoma (bladder cancer, pyelonephritis) will be compared with that of no treatment or chemotherapy after local treatment. Overall analysis as well as analysis by cancer site and intervention method will be performed.	—

Countries

Japan

Contacts

Public ContactShingo Hatakeyama

Hirosaki University Urology

shingoh@hirosaki-u.ac.jp0172-39-5091

Outcome results